Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-847

Good evening Holders,

Since the 24th April 2020 stunning announcement, one(1) question has been burning in my gut......

ASX Announcement 24th April 2020
83% SURVIVAL IN COVID-19 PATIENTS WITH MODERATE/SEVERE ACUTE RESPIRATORY
DISTRESS SYNDROME TREATED IN NEW YORK WITH MESOBLAST’S CELL THERAPY
REMESTEMCEL-L

.. ........" These results contrast with only 9% of ventilator-dependent COVID-19 patients being able to come off
ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at
two major referral hospital networks in New York during the same time period ". ......

My pondering / Question ?
I understand that the Mt Sinai patients were treated under Compassionate use .. BUT why the reference to the above ?

My questions (pondering ) was as follows:-

• Were the Ventilator-dependent COVID-10 patients (which Mt Sinai Patients treated) on maximal care ? ...........Before they received Remestemcel-L ??

• Is there a real prospect (maybe) that the 83% survival ( Mt Sinai ) can be compared to an "assumed" PLACEBO , being the 12% patients treated @ the two major referral hospital networks in New York who hadmaximal care ? That is, can the 12% outcome (patients that were treated at the " two major referral hospital networks in New York during the same time period" ).. be effectively viewed as PLACEBO

Once again sort counsel from my good friend "the Specialist"
Given that ALL patients were on maximal care , does my layman view ( we indirectly have a control Vs placebo look in) have merit ?

Response from the Specialist:
Anjo .. not a silly question. In my view, I think the ASX announcement on 24th April made this clear.
Distinctly REMESTEMCEL-L was behind the 83% Survival

In Conclusion:-Holders - we now await "robust" confirmation of the 300 Patient trial.
As noted previously, FDA requested the increase from 240 to 300 to ensure there is sufficient powering. The fact that another 10 hospitals jumped on board is testament to the Mt Sinai results (and confirmed to me by the "Specialist").

Definitely June is looking very eventful for the Blaster. As they say .. WATCH this space !

One final comment regarding Stem cell competitors.

• Let them Develop (i.e. progress there research).
• When the time is right .. ...........Mesoblast will actively and vigorously defend their patents ( as noted by the awesome Ecool and OP previously).

Huge 2 (two) months coming up !

GLTAH,
Anjo.